Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis
Abstract
:1. Introduction
2. Experimental Section
2.1. Study Design
2.2. Statistical Analysis
3. Results
3.1. Study Population
3.2. Survival Analysis in the Overall Cohort
3.3. Relapse-Free Survival Analysis in the Cohort of Patients Treated with Curative Intent
3.4. Survival Analysis in the Cohort of Patients who Received Chemotherapy for Metastatic Disease
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
Ethics
References
- Pósfai, B.; Kuthi, L.; Varga, L.; Laczó, I.; Révész, J.; Kránicz, R.; Maráz, A. The colorful palette of neuroendocrine neoplasms in the genitourinary tract. Anticancer Res. 2018, 38, 3243–3254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, X.; Liu, D.; Fallon, J.T.; Zhong, M. Distinct genetic alterations in small cell carcinoma from different anatomic sites. Exp. Hematol. Oncol. 2015, 4, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, M.T.; Penson, A.; Desai, N.B.; Socci, N.D.; Shen, R.; Seshan, V.E.; Kundra, R.; Abeshouse, A.; Viale, A.; Cha, E.K.; et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin. Cancer Res. 2018, 24, 1965–1973. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, L.; Pan, C.X.; Yang, X.J.; Lopez-Beltran, A.; MacLennan, G.T.; Lin, H.; Kuzel, T.M.; Papavero, V.; Tretiakova, M.; Nigro, K.; et al. Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients. Cancer 2004, 101, 957–962. [Google Scholar] [CrossRef] [PubMed]
- Choong, N.W.W.; Quevedo, J.F.; Kaur, J.S. Small cell carcinoma of the urinary bladder: The mayo clinic experience. Cancer 2005, 103, 1172–1178. [Google Scholar] [CrossRef] [PubMed]
- La Rosa, S.; Sessa, F.; Uccella, S. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the concept of a heterogeneous group of neoplasms. Endocr. Pathol. 2016, 27, 284–311. [Google Scholar] [CrossRef] [PubMed]
- Bosman, F.T.; Carneiro, F.; Hruban, R.H.; Theise, N.D. WHO Classification of Tumours of the Digestive System, 4th ed.; IARC: Lyon, France, 2010; ISBN 9789283224327. [Google Scholar]
- Magers, M.J.; Lopez-Beltran, A.; Montironi, R.; Williamson, S.R.; Kaimakliotis, H.Z.; Cheng, L. Staging of bladder cancer. Histopathology 2019, 74, 112–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siefker-Radtke, A.O.; Kamat, A.M.; Grossman, H.B.; Williams, D.L.; Qiao, W.; Thall, P.F.; Dinney, C.P.; Millikan, R.E. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J. Clin. Oncol. 2009, 27, 2592–2597. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pasquier, D.; Barney, B.; Sundar, S.; Poortmans, P.; Villa, S.; Nasrallah, H.; Boujelbene, N.; Ghadjar, P.; Lassen-Ramshad, Y.; Senkus, E.; et al. Small cell carcinoma of the urinary bladder: A retrospective, multicenter rare cancer network study of 107 patients. Int. J. Radiat. Oncol. 2015, 92, 904–910. [Google Scholar] [CrossRef] [PubMed]
- National Comprehensive Cancer Network (NCCN). Guidelines—Bladder Cancer Version 4. 2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (accessed on 30 December 2019).
- Kaushik, D.; Frank, I.; Boorjian, S.A.; Cheville, J.C.; Eisenberg, M.S.; Thapa, P.; Tarrell, R.F.; Thompson, R.H. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int. J. Urol. 2015, 22, 549–554. [Google Scholar] [CrossRef] [PubMed]
- Lynch, S.P.; Shen, Y.; Kamat, A.; Grossman, H.B.; Shah, J.B.; Millikan, R.E.; Dinney, C.P.; Siefker-Radtke, A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: Results from a retrospective study at the MD Anderson Cancer Center. Eur. Urol. 2013, 64, 307–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vetterlein, M.W.; Wankowicz, S.A.M.; Seisen, T.; Lander, R.; Löppenberg, B.; Chun, F.K.H.; Menon, M.; Sun, M.; Barletta, J.A.; Choueiri, T.K.; et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer 2017, 123, 4346–4355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cattrini, C.; Cerbone, L.; Rubagotti, A.; Zinoli, L.; Latocca, M.M.; Messina, C.; Zanardi, E.; Boccardo, F. Prognostic variables in patients with non-metastatic small-cell neuroendocrine carcinoma of the bladder: A population-based study. Clin. Genitourin. Cancer 2019, 17, e724–e732. [Google Scholar] [CrossRef] [PubMed]
- Berg, S.; D’Andrea, D.; Vetterlein, M.W.; Cole, A.P.; Fletcher, S.A.; Krimphove, M.J.; Marchese, M.; Lipsitz, S.R.; Sonpavde, G.; Noldus, J.; et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer 2019, 125, 1449–1458. [Google Scholar] [CrossRef] [PubMed]
- Niu, Q.; Lu, Y.; Xu, S.; Shi, Q.; Guo, B.; Guo, Z.; Huang, T.; Wu, Y.; Yu, J. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: A population-based study. Cancer Manag. Res. 2018, 10, 4479–4489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koay, E.J.; Teh, B.S.; Paulino, A.C.; Butler, E.B. Treatment trends and outcomes of small-cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.G.; Stimson, C.J.; Zaid, H.B.; Resnick, M.J.; Cookson, M.S.; Barocas, D.A.; Chang, S.S. Locoregional small cell carcinoma of the bladder: Clinical characteristics and treatment patterns. J. Urol. 2014, 191, 329–334. [Google Scholar] [CrossRef] [PubMed]
N | (%) | ||
---|---|---|---|
Total | 51 | (100%) | |
Sex | Male | 46 | (90.2%) |
Female | 5 | (9.8%) | |
Age at diagnosis, years | Median (range) | 70 | (47–85) |
Symptoms at diagnosis | 38 | (90.5%) | |
ECOG PS | 0 | 22 | (45.8%) |
1–2 | 26 | (54.2%) | |
Stage at diagnosis | I-III | 38 | (74.5%) |
IV | 13 | (25.5%) | |
Histology subtype | NEC | 41 | (80.4%) |
MANEC | 10 | (19.6%) | |
Perioperative chemotherapy + | 11 | (29.7%) | |
Primary lesion resection | 46 | (90.2%) | |
Locally or metastatic residual resection after surgery | 14 | (27.5%) | |
Disease relapse after surgery | 26 | (70.3%) * | |
First-line chemotherapy for advanced disease | 28 | (54.9%) |
Factor | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95%CI | p | HR | 95%CI | p | |
Sex (Male) | 0.99 | 0.30–3.27 | 0.980 | - | - | - |
Age | 1.03 | 0.99–1.07 | 0.163 | - | - | - |
Symptoms at diagnosis | 1.61 | 0.36–7.18 | 0.531 | - | - | - |
ECOG PS (PS 1) | 2.26 | 0.99–5.17 | 0.053 | ns | ns | ns |
Stage (IV) | 2.79 | 1.33–5.85 | 0.007 | 2.52 | 1.19–5.35 | 0.016 |
Histology subtype (NEC) | 1.26 | 0.48–3.30 | 0.642 | - | - | - |
Ki67 | 1.02 | 0.99–1.06 | 0.147 | - | - | - |
Primary lesion resection | 0.62 | 0.24–1.64 | 0.339 | - | - | - |
Factor | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95%CI | p | HR | 95%CI | p | |
Sex (Male) | 1.21 | 0.28–5.13 | 0.800 | - | - | - |
Age | 1.01 | 0.97–1.05 | 0.750 | - | - | - |
Symptoms at diagnosis | 1.25 | 0.29–5.43 | 0.770 | - | - | - |
ECOG PS (PS 1) | 2.40 | 1.04–5.54 | 0.041 | 2.73 | 1.16–6.44 | 0.021 |
Nodal involvement | 1.53 | 0.68–3.44 | 0.301 | - | - | - |
Histology subtype (NEC) | 0.52 | 0.20–1.32 | 0.167 | - | - | - |
Ki67 | 1.02 | 0.99–1.05 | 0.285 | - | - | - |
Perioperative chemotherapy | 0.47 | 0.20–0.14 | 0.096 | 0.42 | 0.17–1.05 | 0.065 |
Factor | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95%CI | p | HR | 95%CI | p | |
Sex (Male) | 0.83 | 0.24–2.85 | 0.770 | - | - | - |
Age | 1.06 | 0.99–1.12 | 0.063 | 1.06 | 1.00–1.11 | 0.036 |
ECOG PS (PS 1) | 1.46 | 0.59–3.62 | 0.420 | - | - | - |
Surgery of primary lesion | 0.68 | 0.23–1.99 | 0.485 | - | - | - |
Stage at diagnosis (stage IV) | 1.07 | 0.47–2.42 | 0.874 | - | - | - |
Previous radical surgery | 1.09 | 0.48–2.45 | 0.844 | - | - | - |
Histology subtype (NEC) | 1.25 | 0.42–3.67 | 0.691 | - | - | - |
Carboplatin-etoposide chemotherapy | 0.47 | 0.20–1.08 | 0.076 | 0.39 | 0.16–0.96 | 0.040 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lamberti, G.; Brizzi, M.P.; Pusceddu, S.; Gelsomino, F.; Di Meglio, G.; Massari, F.; Badalamenti, G.; Riccardi, F.; Ibrahim, T.; Ciccarese, C.; et al. Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. J. Clin. Med. 2020, 9, 1351. https://doi.org/10.3390/jcm9051351
Lamberti G, Brizzi MP, Pusceddu S, Gelsomino F, Di Meglio G, Massari F, Badalamenti G, Riccardi F, Ibrahim T, Ciccarese C, et al. Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. Journal of Clinical Medicine. 2020; 9(5):1351. https://doi.org/10.3390/jcm9051351
Chicago/Turabian StyleLamberti, Giuseppe, Maria Pia Brizzi, Sara Pusceddu, Fabio Gelsomino, Giovanni Di Meglio, Francesco Massari, Giuseppe Badalamenti, Ferdinando Riccardi, Toni Ibrahim, Chiara Ciccarese, and et al. 2020. "Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis" Journal of Clinical Medicine 9, no. 5: 1351. https://doi.org/10.3390/jcm9051351